Impact of an individualized prophylaxis approach on young adults with severe hemophilia

Seminars in Thrombosis and Hemostasis

Volumn 40, Issue 7, 2014, Pages 785-789

  Fernandes, Susana ^a   Carvalho, Manuela ^a   Lopes, Manuela ^a   Araújo, Fernando ^a,b  

^a Universidade do Porto   (Portugal)

^b University of Porto   (Portugal)

Author keywords

bleeding; hemophilia; individualized prophylaxis; young adults

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE;

ADULT; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL EVALUATION; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DRUG SELF ADMINISTRATION; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; MEDICATION COMPLIANCE; METRORRHAGIA; PATIENT COMPLIANCE; PERSONALIZED MEDICINE; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY OF LIFE; SEVERE HEMOPHILIA; YOUNG ADULT; ECONOMICS; FEMALE; FOLLOW UP; HEMORRHAGE; HOSPITAL; MALE; PATHOPHYSIOLOGY; PORTUGAL; PROCEDURES;

ACTIVITIES OF DAILY LIVING; ADULT; FEMALE; FOLLOW-UP STUDIES; HEMOPHILIA A; HEMOPHILIA B; HEMORRHAGE; HOSPITALS, SPECIAL; HUMANS; INDIVIDUALIZED MEDICINE; MALE; PORTUGAL; QUALITY OF LIFE; YOUNG ADULT;

EID: 84928402601     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0034-1394109     Document Type: Article

References (25)

1. Knobe K., Berntorp E. Haemophilia and joint disease: pathophysiology, evaluation and management. Journal of Comorbidity: 2011; 1 1 51 59
2. Coppola A., Tagliaferri A., Di Capua M., Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost: 2012; 38 1 79 94
3. Doria A. S. State-of-the-art imaging techniques for the evaluation of haemophilic arthropathy: present and future. Haemophilia: 2010; 16 (Suppl 5) 107 114
4. Lane S. Successful transfusion of blood. Lancet: 1840; 1 185 188
5. Fischer K., Konkle B., Broderick C., Kessler C. M. Prophylaxis in real life scenarios. Haemophilia: 2014; 20 (Suppl 4) 106 113
6. Donadel-Claeyssens S. European Paediatric Network for Haemophilia Management Current co-ordinated activities of the PEDNET (European Paediatric Network for Haemophilia Management). Haemophilia: 2006; 12 2 124 127
7. Ar M. C., Vaide I., Berntorp E., Björkman S. Methods for individualising factor VIII dosing in prophylaxis. Eur J Haematol Suppl: 2014; 76 16 20
8. Coppola A., Franchini M. Target of prophylaxis in severe haemophilia: more than factor levels. Blood Transfus: 2013; 11 3 327 329
9. van Dijk K., Fischer K., van der Bom J. G., Scheibel E., Ingerslev J., van den Berg H. M. Can long-term prophylaxis for severe haemophilia be stopped in adulthood? Results from Denmark and the Netherlands. Br J Haematol: 2005; 130 1 107 112
10. Manco-Johnson M. J., Abshire T. C., Shapiro A. D., et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med: 2007; 357 6 535 544
11. Gringeri A., Lundin B., von Mackensen S., Mantovani L., Mannucci P. M. ESPRIT Study Group A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost: 2011; 9 4 700 710
12. Srivastava A., Brewer A. K., Mauser-Bunschoten E. P., et al. Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia: 2013; 19 1 e1 e47
13. Richards M., Williams M., Chalmers E., et al. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol: 2010; 149 4 498 507
14. Gringeri A., Lambert T., Street A., Aledort L. Adolescent/Adult Prophylaxis Expert Working Group of the International Prophylaxis Study Group. Tertiary prophylaxis in adults: is there a rationale? Haemophilia: 2012; 18 5 722 728
15. Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus: 2012; 10 2 165 168
16. Astermark J., Petrini P., Tengborn L., Schulman S., Ljung R., Berntorp E. Primary prophylaxis in severe haemophilia should be started at an early age but can be individualized. Br J Haematol: 1999; 105 4 1109 1113
17. Berntorp E., Fischer K., Miners A. Models of prophylaxis. Haemophilia: 2012; 18 (Suppl 4):136 140
18. Fischer K. Prophylaxis for adults with haemophilia: one size does not fit all. Blood Transfus: 2012; 10 2 169 173
19. Collins P. W. Personalized prophylaxis. Haemophilia: 2012; 18 (Suppl 4) 131 135
20. Coppola A., Franchini M., Tagliaferri A. Prophylaxis in people with haemophilia. Thromb Haemost: 2009; 101 4 674 681
21. Noone D., Mahony B. O., Prihodova L. A survey of the outcome of prophylaxis, on-demand or combined treatment in 20-35 year old men with severe haemophilia in four European countries. Haemophlia: 2011; 17 e842 e843
22. Manco-Johnson M. J., Kempton C. L., Reding M. T., et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost: 2013; 11 6 1119 1127
23. Tagliaferri A., Coppola Afeola G., Molinari A. C., et al. Impact on healthcare costs and quality of life of secondary prophylaxis in adolescent and adult patients with severe haemophilia A: the POTTER study. J Thromb Haemost: 2013; 11 (Suppl 2) 321 322 (abstract)
24. Fischer K., Astermark J., van der Bom J. G., et al. Prophylactic treatment for severe haemophilia: comparison of an intermediate-dose to a high-dose regimen. Haemophilia: 2002; 8 6 753 760
25. Makris M., Calizzani G., Fischer K., et al. The European Haemophilia Network (EUHANET). Blood Transfus: 2014; 12 (Suppl 3) s515 s518